Ribociclib plus hormone therapy for recurrent breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive
- Have HER2-negative cancer (confirmed by specific lab test results on your most recent tumor tissue)
- Have cancer that has come back only in the local area (breast on the same side, nearby lymph nodes, or chest wall)—not spread to distant organs
- Be able to start or continue hormone therapy by mouth as planned, and be able to swallow pills
- Have recent blood, liver, kidney, heart tracing (ECG), and electrolyte results that meet safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
Hear when a new Locoregional Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.